Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 2Breast Neoplasms 2Stomatitis 1Rectal Neoplasms 1Periodontitis 1Neoplasms, Plasma Cell 1Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Febrile Neutropenia 1EGFR-Mutant Lung Cancer 1Deglutition Disorders 1Communication Disorders 1Colorectal Neoplasms 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Brain Neoplasms 1Advanced Breast Cancer 1Adenocarcinoma 1

Interventions

Fulvestrant 18Letrozole 8Anastrozole 6Capecitabine 5palbociclib 4olaparib 4Paclitaxel 4Goserelin 4Docetaxel 4pyrotinib 3exemestane 3Injections 3toripalimab 2sacituzumab govitecan 2ribociclib 2eribulin 2elacestrant 2abemaciclib 2Vinorelbine 2Trastuzumab 2FCN-437c 2Everolimus 2Dasatinib 2Aromatase Inhibitors 2Alpelisib 2Albumin-Bound Paclitaxel 2AZD9833 2vandetanib 1trastuzumab deruxtecan 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Breast Cancer × Lead × Clear all
NCT05085002 2026-05-14

A Study of Lerociclib in Participants With Advanced Breast Cancer

EQRx International, Inc.

Phase 2 Terminated
100 enrolled 14 charts
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡